A structured assessment process can determine compliance to lifecycle process-validation requirements for biopharmaceuticals.
Ajay Pazhayattil
Advertisement
Articles by Ajay Pazhayattil
483s and Warning Letters Point to Inadequate Quality Oversight
FDA’s focus on the quality culture and its request for quality metrics may ensure a successful company-CMO relationship.
Advertisement
Latest Updated Articles
Quality Metrics and CMO AgreementPublished: May 15th 2017 | Updated:
- Solving Pharma’s Quality Unit Identity Crisis
Published: July 1st 2020 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
2
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
3
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
